Company news

Axsome Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

May 31, 2022

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

May 30, 2022

Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry

May 17, 2022

Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month

May 15, 2022

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

May 8, 2022

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 1, 2022

Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine

May 1, 2022

Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022

April 24, 2022

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience

March 27, 2022

Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum

March 10, 2022

Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

March 1, 2022

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 28, 2022

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

February 14, 2022

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

November 7, 2021

Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

October 19, 2021

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

October 17, 2021

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

September 15, 2021

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

September 13, 2021

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

August 22, 2021

Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

August 8, 2021

Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression

August 8, 2021

Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021

July 14, 2021

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

June 14, 2021

Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 9, 2021

Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month

May 6, 2021

Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021

April 26, 2021

Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder

April 25, 2021

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 28, 2021

Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

February 15, 2021

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

December 30, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

December 30, 2020

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation

December 7, 2020

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

December 1, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder

November 30, 2020

Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform

November 3, 2020

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform

November 3, 2020

Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 2, 2020

Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020

October 27, 2020

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

September 28, 2020

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

September 23, 2020

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

September 20, 2020

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

September 16, 2020

Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder

September 13, 2020

Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress

September 9, 2020

Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

September 7, 2020

Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting

August 30, 2020

Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting

August 27, 2020

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine

August 19, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.